



To whom it may concern:

February 1, 2022
Whiz Partners Inc.

Signature on Japan Impact-Driven Financing Initiative

Whiz Partners Inc. (headquarters: Minato-ku, Tokyo; president & CEO, member of the board: Atsushi Matsumura; hereinafter referred to as “the company”) has put its signature on the Japan Impact-Driven Financing Initiative (secretariat: Japan Social Innovation and Investment Foundation) (Exhibit) that financial institutions declare actively addressing social and environmental issues with impact-driven management.

Impact investment is aimed at generating positive and measurable social and environmental impacts in addition to financial returns (performance). Traditional investing is measured on the two dimensions of risk and return. An investment that incorporates the third dimension, impact, into the traditional ones, and that is intended to achieve both social and financial returns by grasping social and environmental changes and the effects that occur as a result of business activities is called an impact investment.

The Japan Impact-Driven Financing Initiative will promote impact investment through cooperation and collaboration between diverse and multiple financial institutions that believe that the purpose of financial institutions is to actively address social and environmental issues by holistically understanding the impact. The initiative has been signed by twenty-seven financial institutions, including the company.

For the Healthcare New Platform Fund^{*1} whose offering and investment were started in September 2021, the company aims to expand the following social impacts through a high degree of expertise in the whole pharmaceutical industry and corporate management ability of the whole company group, agile and flexible business partnership ability regardless of nationality and business category, and management policy and business promotion of investee companies.

(i) Enhancement of the access to healthcare

The World Bank and World Health Organization (WHO) reported that half of the world's



population did not have access to basic health services in 2017. The company contributes to the enhancement of access to healthcare around the world through high-mix, low-volume drug discovery and increasing the efficiency and industrialization of the drug discovery process and a reduction in drug development costs.

(ii) Creation of new platform companies in the pharmaceutical sector facing industrial structure change

In the pharmaceutical sector, there is an industrial structure change in the drug development process from the vertical integration model to the horizontal specialization model using outsourcing. To respond to the horizontal specialization model, the company builds healthcare platform companies with global competitiveness and then assists in the achievement of sustainable and solid infrastructure development in the healthcare area and contributes to an increase in healthy life spans.

(iii) Reduction in risk of infection under the pandemic

For contributing to the health of people, the company realizes the rapid supply of vaccines, which became an issue during the recent infection pandemic, through the establishment of dual-use messenger RNA API (active pharmaceutical ingredient) manufacturing plants that could manufacture bio-pharmaceuticals in ordinary times and the switch to manufacturing of vaccines in an urgent time.

Comment from Atsushi Matsumura, President & CEO, Member of the Board

The Healthcare New Platform Fund, which is managed by the company, establishes companies by itself, raises money, and attracts the required talent and technology to actively promote business development, become deeply involved in management, and actively address the social issues of the enhancement of access to healthcare, increase in healthy life spans, and reduction in the risk of infection. Therefore, we think that making and executing an impact-driven business plan enable us to secure consistency as a company. We are obligated to provide financial returns (performance) to investors as a fund, and besides providing financial returns, we are responsible for ensuring that investee companies continuously incorporate the mechanism for determining judgments according to social goals, such as the SDGs, into corporate management. Based on the assumption that impact investment is an optimum approach to fulfill the responsibility, we would like to largely contribute to actively addressing global environmental and social issues through impact-driven investment.



***¹Healthcare New Platform Fund**

The fund is an investment limited partnership that was established on September 28, 2021, for which the company serves as an unlimited liability partner. The fund makes investments mainly in new healthcare platform companies, including Axcelead, Inc., the first healthcare platform company in Japan, and Arcalis, Inc., which set up a plant in Minamisoma-shi, Fukushima Prefecture, and operates the sole CDMO business in Japan for APIs and drug products of messenger RNA pharmaceuticals and vaccine. For more details, please see the press release at time of establishment (http://www.whizp.com/wp-content/uploads/2021/10/1894_03.pdf).

(Exhibit) [TOP | Japan Impact-driven Financing Initiative \(impact-driven-finance-initiative.com\)](#)

[Contact] Eri Yokota, public relations manager yokota@whizp.com